Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 5/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1388427 | 0.83 | TSHR (0.48) | IDO1MAOBPKMTACR1 | |
| SCHEMBL20999089 | 0.82 | ESR1 (0.47) | IDO1MAOBAGXTFFAR1TACR1 | |
| SCHEMBL350082 | 0.82 | IDO1 (0.46) | IDO1MAOBAGXTTACR1 | |
| SCHEMBL26245888 | 0.79 | CYP4F2 (0.46) | IDO1MAOBFFAR1CYP1A2CYP2C19 | |
| SCHEMBL171782 | 0.77 | IDO1 (0.68) | IDO1MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL20795016 | 0.76 | ESR1 (0.50) | IDO1MAOBFFAR1 | |
| SCHEMBL20795882 | 0.75 | IDO1 (0.43) | IDO1MAOBAGXTFFAR1TACR1 | |
| SCHEMBL487468 | 0.74 | IDO1 (0.48) | IDO1MAOBAGXTFFAR1 | |
| SCHEMBL20999104 | 0.74 | IDO1 (0.50) | IDO1MAOBAGXTHTR2AHTR2C | |
| SCHEMBL20347891 | 0.74 | TSHR (0.46) | IDO1MAOBAGXTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | NR3C1, NR3C2, MC2R | IDO1 1110/4885MAOB 2962/4885AGXT 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.